Volume 7.35 | Sep 10

Mammary Cell News 7.35 September 10, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
 
TOP STORY
PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2 Positive Breast Cancer to Reverse Trastuzumab Resistance
Researchers showed previously that Notch-1 is required for trastuzumab resistance in ErbB-2 positive breast cancer. Here, they evaluated mechanisms by which ErbB-2 attenuates Notch signaling and how this is reversed by trastuzumab or lapatinib. [Clin Cancer Res] Abstract
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Downregulation of MicroRNA-362-3p and MicroRNA-329 Promotes Tumor Progression in Human Breast Cancer
To explore novel regulatory mechanisms of p130Cas expression, investigators studied the effect of microRNAs on p130Cas expression in human breast cancer MCF7 cells. [Cell Death Differ] Abstract

Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation
Investigators demonstrated that the physical contact of breast cancer cells with mesenchymal stem cells is a potential modulator of trastuzumab response by activation of nonreceptor tyrosine kinase c-Src and down regulation of phosphatase and tensin homolog. [Sci Rep] Full Article

Hypoxia-Induced Carbonic Anhydrase IX Facilitates Lactate Flux in Human Breast Cancer Cells by Non-Catalytic Function
Researchers studied the mechanisms of regulated lactate transport in MCF-7 human breast cancer cells. Under hypoxia, expression of monocarboxylate transporter (MCT)1 and MCT4 remained unchanged, while expression of carbonic anhydrase IX was greatly enhanced. [Sci Rep] Full Article

Monocyte-Derived Macrophage Assisted Breast Cancer Cell Invasion as a Personalized, Predictive Metric to Score Metastatic Risk
The authors demonstrated by which variability in macrophage expression of cysteine cathepsins, their inhibitor cystatin C, and kinase activation can be used to train a multivariate model and score patients for invasion risk. [Sci Rep] Full Article

Forkhead Box K2 Modulates Epirubicin and Paclitaxel Sensitivity through FOXO3a in Breast Cancer
Researchers demonstrated that forkhead box (FOX)K2 has a central role in mediating the cytotoxic drug response in breast cancer. Clonogenic and cell viability assays showed that enhanced FOXK2 expression sensitizes MCF-7 breast cancer cells to paclitaxel or epirubicin treatment, whereas FOXK2 depletion by small interfering RNAs confers drug resistance. [Oncogenesis] Full Article

Apoptotic Effect of Tannic Acid on Fatty Acid Synthase Over-Expressed Human Breast Cancer Cells
Scientists assessed the effect and therapeutic potential of tannic acid (TA) on fatty acid synthase (FAS) over-expressed breast cancer cells, and as a result, TA had been proven to possess the functions of inhibiting intracellular FAS activity, down-regulating FAS expression in human breast cancer MDA-MB-231 and MCF-7 cells, and inducing cancer cell apoptosis. [Tumor Biol] Abstract

IM-412 Inhibits the Invasion of Human Breast Carcinoma Cells by Blocking FGFR-Mediated Signaling
Researchers examined the inhibitory effect of 3-(2-chlorobenzyl)-1,7-dimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione (IM-412) on epithelial-to-mesenchymal transition (EMT) pathways and invasiveness in triple-negative breast cancer cells since the TGF-β signaling pathway is a typical signaling pathway that functions in EMT. [Oncol Rep] Abstract

A Novel ER–Microtubule-Binding Protein, ERLIN2, Stabilizes Cyclin B1 and Regulates Cell Cycle Progression
The authors revealed that endoplasmic reticulum (ER) lipid raft-associated protein 2 (ERLIN2) is a spatially and temporally regulated ER–microtubule-binding protein that has an important role in cell cycle progression by interacting with and stabilizing the mitosis-promoting factors. Downregulation of ERLIN2 results in cell cycle arrest, represses breast cancer proliferation and malignancy and increases sensitivity of breast cancer cells to anticancer drugs. [Cell Discov] Full Article

CLINICAL RESEARCH

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
In a Phase I clinical study, the catalytic Akt inhibitor AZD5363 induced partial responses in breast and ovarian cancer patients with tumors containing AKT1E17K mutations. [Mol Cancer Ther] Abstract | Full Article

Pegfilgrastim Administration after 24 or 72 or 96 H to Allow Dose-Dense Anthracycline- and Taxane-Based Chemotherapy in Breast Cancer Patients: A Single-Center Experience within the GIM2 Randomized Phase III Trial
To evaluate the safest timing of pegfilgrastim administration in dose-dense anthracycline- and taxane-based chemotherapy, three different cohorts of patients enrolled in the Gruppo Italiano Mammella (GIM) 2 study and treated at the coordinating center received pegfilgrastim 24 hours or 72 hours or 96 hours after chemotherapy. [Support Care Cancer] Abstract

Request a Copy: Breast Cancer Wallchart
 
REVIEWS
The Roles of ncRNAs and Histone-Modifiers in Regulating Breast Cancer Stem Cells
Growing evidence shows that cancer stem cells are regulated by non-coding RNA (ncRNA), including microRNAs and long non-coding RNAs (lncRNAs), and histone-modifiers, such as let-7, miR-93, miR-100, HOTAIR, Bmi-1 and EZH2. The authors review the roles of microRNAs, lncRNAs and histone-modifiers especially Polycomb family proteins in regulating breast cancer stem cells. [Protein Cell] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
 
INDUSTRY NEWS
OBI Pharma to Unblind Its Phase II/III Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016
OBI Pharma, Inc. announced it plans to unblind its flagship OBI-822/821 Phase II/III clinical trial by March 2016. [OBI Pharma, Inc.] Press Release

NIH Grants Seek Best Ways to Combine Genomic Information and EHRs
A dozen awards from the National Institutes of Health will support research that incorporates DNA sequence information into electronic medical records. The goal of research conducted by the Electronic Medical Records and Genomics network is to better understand the genomic basis of disease and to tailor medical care to individual patients based on their genomic differences. [National Institutes of Health] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Society for Immunotherapy of Cancer (SITC) 2015
November 4-8, 2015
National Harbor, Maryland

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Research Associate – Breast Cancer Invasion / Extracellular Matrix / Proteomics / Microscopy (University of Liverpool)

NEW Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Fellowship – Cancer Biology (Massachusetts General Hospital Cancer Center/Harvard Medical School)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Proteomic, Glycomic and Autoantibody Biomarkers of Cancer (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Cancer Biology (National Cancer Institute)

Postdoctoral Position – Cancer Biology (Northwestern University)

Postdoctoral Position – Inflammation & Breast Tumor Metastasis (Stephenson Cancer Center)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us